Compare Adaptive Biotechnologies Corp (ADPT) vs Five Below Inc (FIVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Five Below Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.08 (market cap $3.33B), while Five Below Inc trades at $179.14 (market cap $9.75B). The key difference: Five Below Inc is far larger — about 2.9× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | FIVE | |
|---|---|---|
Market Cap | $3.33B | $9.75B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $247.71 |
52-Week Low | $10.24 | $128.78 |
Enterprise Value | $3.19B | $10.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Five Below (FIVE) trades at $176.25, down 3.39% with a bearish technical signal despite strong earnings beats. The company shows solid revenue growth from $3.88B in 2025 to projected $5.1B in 2026, with net income margin improving to 8.67%. Recent news highlights digital marketing success and leadership appointments driving customer engagement. Technical indicators show oversold conditions with RSI at 24.82, while support levels begin at $174.
Analyst consensus remains strongly bullish with 58% buy ratings and $253 price target, representing 44% upside. Key risks include execution of expansion plans and consumer spending sensitivity. The combination of strong fundamentals, positive analyst sentiment, and current technical oversold conditions presents a compelling opportunity for growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
